Lancet Gastroenterology & Hepatology

Article	Citations
Double Duty	1004
Correction to Lancet Gastroenterol Hepatol 2022; 7: 152–60	364
Stringent criteria for withdrawal of biologics in ulcerative colitis – Authors' reply	335
ESWL pancreatitis: yet another post-procedural pancreatitis to worry about?	335
Improving liver cancer care across Europe	333
Interim evaluation of the colorectal cancer screening programme in the Netherlands	327
Trends in alcohol-specific deaths in the UK and industry responses	287
Controversy over colonoscopy for colorectal cancer screening	272
Global burden of occult hepatitis B virus infection: where we are and what to do	267
Procalcitonin-guided reduction of antibiotic use in acute pancreatitis	259
Comparison of trends in early-onset colorectal cancer in North America and Europe – Authors' reply	221
Comparison of trends in early-onset colorectal cancer in North America and Europe	211
Standardising early liver transplantation for severe alcohol-related hepatitis – Authors' reply	199
Disparities in gastroenterology grand rounds speakerships in the USA	195
USPSTF: colorectal cancer screening in the US from 45 years	189
Challenging stigma around alcohol misuse	176
Research in Brief	175
Representation and reporting of diverse groups in randomised controlled trials of pharmacological agents in inflammatory bowel disease: a systematic review	170
Correction to Lancet Gastroenterol Hepatol 2021; 6: 875	170
Lessons from a trial of colesevelam for bile acid diarrhoea	167
Virtual ESMO World Congress on Gastrointestinal Cancer 2021	158
Outcomes of minimum unit pricing for alcohol in Scotland	156
A personalised taper-to-target strategy with adalimumab in Crohn's disease	155
Immune checkpoint inhibitors in colorectal cancer: dream and reality	153
Safety and tolerability of KAN-101, a liver-targeted immune tolerance therapy, in patients with coeliac disease (ACeD): a phase 1 trial	152

Viral hepatitis in Asia-Pacific: a post-COVID-19 reset	146
The quest for the ideal NASH biomarker	145
Research in Brief	145
Predicting clinical outcomes in people with NAFLD: no need for a crystal ball?	134
Correction to Lancet Gastroenterol Hepatol 2021; 6: 933–46	133
Alcohol-related harms and the case for minimum unit pricing	123
Vedolizumab in paediatric IBD: a huge step forward but not there yet	116
Flux Gourmet: a visual feast with a starved social mission	116
Séverine Vermeire: advancing patient-centred research in IBD	110
Peroral endoscopic myotomy versus pneumatic dilation in treatment-naive patients with achalasia – Authors' reply	109
Living	108
Faecal microbiota transplantation for first and second episodes of Clostridioides difficile infection	104
Uncoupler therapy for NAFLD: is flushing a possible harbinger of a safety concern?	104
Research in Brief	102
Ensuring patients with malignant bowel obstruction are central in research and clinical decisions	98
How can I improve my gut health if I am on a special diet?	98
Ingestion of high-power magnets: cause for concern	97
Correction to Lancet Gastroenterol Hepatol 2021; 6: 569–77	96
Launch of the UN Group of Friends to eliminate hepatitis	89
Research in Brief	88
The Liver Meeting 2023	86
Endoscopic screening for oesophageal cancer: empowering artificial intelligence with a high-quality examination	85
Research in Brief	84
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated rand	83
New WHO guidance for country validation of viral hepatitis B and C elimination	81
A whole-food exclusion diet as monotherapy for Crohn's disease	80
Research in Brief	80
Reducing disparities in training in inflammatory bowel disease	79
Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial	78
The HEPSANET score to assess treatment eligibility of chronic hepatitis B in Africa	78
Ranking treatments in the network meta-analysis should consider the certainty of evidence – Authors' reply	75
The role of ERAS in robotic pancreaticoduodenectomy – Authors' reply	75
Oral faecal microbiota transplantation in ulcerative colitis – Authors' reply	74
Research in Brief	73
The Other Dark Matter	73
Terlipressin for hepatorenal syndrome: opportunities and challenges	73
Can genetically engineered pig livers offer patients precious time?	71
Hepatocellular carcinoma: measures to improve the outlook in sub-Saharan Africa	71
Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium	70
Gavi's green light for hepatitis B birth dose vaccination in Africa	70
The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas	69
Oral faecal microbiota transplantation in ulcerative colitis	68
Time to scale up testing and treatment for HBV and HCV in the WHO Eastern Mediterranean Region	66
Simplifying the path to elimination of hepatitis C	65
Closing the gender gap in gastroenterology leadership: the need for effective and comprehensive allyship	65
ECCO'24	64
17th Congress of ECCO	63
Haematopoietic stem-cell transplantation in Crohn's disease	63
Crunching the numbers for viral hepatitis	63
Covered versus bare-metal stenting in chronic mesenteric ischaemia – Authors' reply	63

Giada Sebastiani: a leading voice on liver fibrosis	61
Global differences in the management of alcohol-associated hepatitis	61
Seeing C diff differently	61
Treatment withdrawal in Crohn's disease: slowly becoming clearer	61
Mystery outbreak of severe acute hepatitis in children	60
Computer-aided detection in real-world colonoscopy: enhancing detection or offering false hope?	59
Robotic pancreatoduodenectomy: preparing for the future	58
Peroral endoscopic myotomy versus pneumatic dilation in treatment-naive patients with achalasia: 5-year follow-up of a randomised controlled trial	58
Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study	58
Enterobius vermicularis infection associated with positive faecal occult blood testing and eosinophilia	57
Rusfertide for iron overload in haemochromatosis	56
Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial	55
Spleen stiffness to identify clinically significant portal hypertension	55
Hypovolaemic phlebotomy to reduce the need for perioperative transfusion: a price worth paying?	54
Vedolizumab for prevention of recurrence of Crohn's disease	54
International consensus statement on microbiome testing in clinical practice	54
Correction to Lancet Gastroenterol Hepatol 2023; 8: 976–89	54
Decrease in uptake of SARS-CoV-2 vaccine in patients with inflammatory bowel disease on intravenous biological therapy	53
Implementing metabolic dysfunction-associated steatotic liver disease guidelines in patients with type 2 diabetes	53
The urgent need to end hepatitis B stigma and discrimination	53
Promoting equity in inflammatory bowel disease: a global approach to care	51
Aldafermin in non-alcoholic steatohepatitis: a cautionary tale for trial design	50
Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a mult	49
Psychological therapies in inflammatory bowel disease	49
A national programme to scale-up decentralised hepatitis C point-of-care testing and treatment in Australia	49
Efruxifermin in non-alcoholic steatohepatitis	49
Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial	48
High 10-year mortality in alcohol-related liver disease: where do we go from here?	48
Under-representation of the WHO African region in clinical trials of interventions against hepatitis B virus infection	48
Less is more: rethinking colorectal cancer resection strategies in Lynch syndrome	48
Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study	47
Local ablation in pancreatic cancer: some answers and more questions	47
The effect of expectancy versus actual gluten intake on gastrointestinal and extra-intestinal symptoms in non-coeliac gluten sensitivity: a randomised, double-blind, placebo-controlled, international,	47
Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study	46
Trends and levels of the global, regional, and national burden of appendicitis between 1990 and 2021: findings from the Global Burden of Disease Study 2021	46
LGBTQIA+ affirming palliative care and communication in liver transplantation	46
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial	45
International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement	45
Top ten research priorities for alcohol use disorder and alcohol-related liver disease: results of a multistakeholder research priority setting partnership	44
Reset after RESET: insights from a negative trial in coeliac disease	43
Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease	42
Antimicrobial susceptibility testing for Helicobacter pylori comes of age	41
SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question	41
Universal hepatitis C virus screening and treatment as part of prenatal care	41
Faecal microbiota transplantation for first and second episodes of Clostridioides difficile infection – Authors' reply	41
Affordable treatment and political commitment are crucial to eliminate hepatitis C globally	41
A new chapter in the campaign to eliminate viral hepatitis?	41
Infliximab discontinuation in patients with ulcerative colitis	41
The changing prevalence of functional constipation: why words matter	40
Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy	39
Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): 10-year follow-up of an open-label, non-inferiority, randomised controlled trial	39
Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic	39
Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial	38
Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis	38
Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement	38
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial	37
Addressing unmet needs from a new frontier of IBD: the South Asian IBD Alliance	37
Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial	35
Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroentero	35
Effect of prophylactic endoscopic clip placement on clinically significant post-endoscopic mucosal resection bleeding in the right colon: a single-centre, randomised controlled trial	35
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives	34
Features of gastrointestinal amyloidosis – Authors’ reply	34
A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial	34
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma	34
A call for advocacy and patient voice to eliminate hepatitis B virus infection	34
Treatment de-escalation in Crohn's disease – Author's reply	34
Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial	34
Warburg: father of the metabolic approach to cancer	33
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial	32
Prevention of post-ERCP pancreatitis: the search continues	32
EASL Congress 2024	32
Hepatitis C epidemic among Rohingya refugees in Cox's Bazar: a public health emergency	31
Transmural healing as a therapeutic goal in Crohn's disease: a systematic review	31
Common mental disorders in irritable bowel syndrome: pathophysiology, management, and considerations for future randomised controlled trials	31
No accident: the UK infected blood scandal	31
Intrahepatic cholestasis of pregnancy: are we expecting too much from ursodeoxycholic acid?	31
Chronic Boom	30
Inflammatory bowel disease health care for LGTBQIA+ patients	30
Gastric examination by guided capsule endoscopy: a new era	29
Exploring novel avenues for neoadjuvant treatment of hepatocellular carcinoma	29

Expanding community engagement and advocacy in chronic viral hepatitis	29
The impact of COVID-19 on hepatitis services and civil society organisations	29
Bridging the gap to achieve viral hepatitis mortality targets	29
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial	28
Lucky: Learning to Live Again	27
Metachronous colorectal cancer risk according to Lynch syndrome pathogenic variant after extensive versus partial colectomy in the Netherlands: a retrospective cohort study	27
Integration of public health measures for NAFLD into India's national programme for NCDs	27
Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America	26
The surety or otherwise of leaving chronic hepatitis B untreated	26
Tackling obesity: drugs are only part of the solution	26
The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis	25
Ultra-processed foods and human health: from epidemiological evidence to mechanistic insights	25
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial	25
Global multi-stakeholder endorsement of the MAFLD definition	24
Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial	24
Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial	24
Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicent	23
Global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium	23
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based th	23
Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual	23
Top 10 research priorities for irritable bowel syndrome: results of a James Lind Alliance priority setting partnership	23
The case for reducing the use of diagnostic upper and lower gastrointestinal endoscopy	23
Barriers to the management of alcohol use disorder and alcohol-associated liver disease: strategies to implement integrated care models	23
Augmenting colonoscopy with AI: insights and future directions	22
Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial	22
Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre randomised controlled trial	22
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled	22
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension	22
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, r	22
A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial	22
Correction to Lancet Gastroenterol Hepatol 2023; 8: 1005–14	21
Correction to Lancet Gastroenterol Hepatol 2022; 7: 736–46	21
Correction to Lancet Gastroenterol Hepatol 2017; 2: 103–11	21
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept t	20
Regional disparities of infections in cirrhosis: a call for action	20
Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium	20
Correction to Lancet Gastroenterol Hepatol 2022; 7: 617–26	19
Immunotherapy in biliary tract cancer: are we finally on the right path?	19
Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial	19
Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease	19
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study	19
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial	18
Viral hepatitis: time for action	18
The ileoanal pouch: the next frontier in inflammatory bowel disease	18
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease – Authors’ reply	18
The Invisible Extinction	18
Harms with placebo in trials of biological therapies and small molecules as induction therapy in inflammatory bowel disease: a systematic review and meta-analysis	18
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease	17
Research in Brief	17
Monitoring and treatment of Wilson disease: progress and challenges	17
Digestive Disease Week 2023	17
Ramucirumab plus paclitaxel for gastric cancer in China	17
Liver disease admissions in the UK are increasing, urgently needing local and national solutions	16
Hepatitis C in pregnancy and the TiP-HepC registry	16
Investigation and management of Wilson's disease: a practical guide from the British Association for the Study of the Liver	16
Endoscopic features of gastrointestinal amyloid light-chain amyloidosis	16
Towards health equity: the urgent need for upstream intervention studies in gastroenterology and hepatology	16
Resmetirom for NASH: balancing promise and prudence	15
The status quo of gastroenterology training in the UK	15
Research in Brief	15
Improving equity and access to bariatric surgery	15
Breaking the therapeutic ceiling in drug development in ulcerative colitis	15
Addressing the rise of early-onset colorectal cancer	15
16th Congress of the European Crohn's and Colitis Organisation	14
COVID-19: Colorectal cancer endoscopic surveillance in IBD	14
Poor Little Sick Girls: A Love Letter to Unacceptable Women	14
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer	14
Food insecurity in the UK: a public health issue left to fester	14
Expression of concern—Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre random	14
Let this radicalise you	14
Rare cause of dysphagia in a young woman	14
The need for a reliable non-invasive diagnostic biomarker for eosinophilic oesophagitis	14
Septic arthritis: a presentation of Crohn's disease	14
Research in brief	14
Correction to Lancet Gastroenterol Hepatol 2022; 7: 747–54	14
Bringing organ preservation closer for selected patients with rectal cancer	14
Distilling the message: Irish plans for alcohol warning labels	13
Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus	13
Gastrointestinal services in India during COVID-19: does governance matter?	13
Inflammatory bowel disease in Lebanon: a plea for help	13
Local and systemic therapy in liver cancer: the quest for synergy	13
Let's talk toilets	13
Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere	13
Research in Brief	13
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study	13
Acute severe ulcerative colitis: confronting an intensified stressor during the COVID-19 pandemic	12
Harnessing the power of hepatitis B screening programmes: the I REACH OUT model	12
Uncoupler therapy for NAFLD: is flushing a possible harbinger of a safety concern? – Authors' reply	12
Gluten and non-coeliac gluten sensitivity: the nocebo effect and future avenues	12
Skin changes in long-term Wilson's disease	12
Closing toilets: more than a public inconvenience	12
Wendy Spearman: tackling liver disease in sub-Saharan Africa	11
The living organ donor as patient	11
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial	11
Water and sanitation for all	11